Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Infrared Light Causes Organic Nanoparticles to Heat Up and Cook Cancer Cells

By BiotechDaily International staff writers
Posted on 06 Dec 2012
Novel organic nanoparticles that generate heat when exposed to infrared light effectively killed colorectal cancer cells in a cell-culture model system.

Investigators at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) developed conjugated polymer nanoparticles (PNs) consisting of 2-ethylhexyl cyclopentadithiophene copolymerized with 2,1,3-benzothiadiazole (for nano-PCPDTBT) or 2,1,3-benzoselenadiazole (for nano-PCPDTBSe). The PNs were stable in aqueous media and showed no significant toxicity up to one mg/mL. Upon exposure to infrared light at 808 nm, the PNs generated temperatures above 50 degrees Celsius.

Experiments were carried out to test the effect of the PNs on cultures of RKO and HCT116 colorectal cancer cells.

Results published in the October 5, 2012, online edition of the journal Macromolecular Bioscience revealed that exposure to infrared light for five minutes killed more than 80% of the cells at nano-PCPDTBSe concentrations above 100 micrograms/mL, while at concentrations above 62 micrograms/mL for nano-PCPDTBT, more than 90% of cells were killed.

“The results of this study demonstrate how new medical advancements are being developed from materials science research,” said senior author Dr. Nicole H. Levi-Polyachenko, assistant professor of plastic and reconstructive surgery at Wake Forest Baptist Medical Center. “There is a lot more research that needs to be done so that these new nanoparticles can be used safely in patients, but the field of electrically-conductive polymers is broad and offers many opportunities to develop safe, organic nanoparticles for generating heat locally in a tissue. We are very enthusiastic about future medical applications using these new nanoparticles, including an alternative approach for treating colorectal cancer.”

Related Links:
Wake Forest Baptist Medical Center


Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.